Risk stratification of patients with TP53-mutated myeloproliferative neoplasms
Leukemia · 2026
DOI: 10.1038/s41375-026-02885-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, 2026. Verfasst von Benjamin Rolles und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Mutation, Myeloproliferative Disorders, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Krebshilfe (German Cancer Aid), NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we analyzed data from 1540 patients treated at four specialized cancer centers. Among them, 1429 had wildtype TP53 and 111 had mutations in the TP53 gene. At first MPN diagnosis, 32% had polycythemia vera, 39% had essential thrombocythemia, and 25% had primary myelofibrosis. Among all MPN patients with TP53 mutations, presence of fibrosis in the bone marrow (hazard ratio (HR): 3.84, 95% CI: 1.98-7.43), multi-hit TP53 mutation status (HR: 2.74, 95% confidence interval (CI): 1.52-4.97), and higher PHANTM score (HR: 1.87, 95% CI: 1.02-3.42) were associated with worse OS in a multivariable analysis. Based on these variables, we developed a risk model to identify TP53-mutated MPN patients who are at high risk for inferior OS. Median OS from time of TP53 detection was 0.5 years in high-risk patients, compared to 2.3 years for patients with intermediate risk and 6.3 years for patients with low risk. This scoring system may help refine risk stratification for chronic phase MPN patients harboring TP53 aberrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- Hematology Division, VA Palo Alto Health Care System, Palo Alto, CA, USA.
- Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Internal Medicine, Section of Medical Oncology and Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
- Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
- Department of Medicine, Mass General Brigham, Salem Hospital, Salem, MA, USA.
ORCID-Profile: Benjamin Rolles, Cilomar Martins de Oliveira Filho, Jan Philipp Bewersdorf, Matthew Schwede, James England, Marlise R Luskin, Daniel J DeAngelo, Shai Shimony, Lachelle D Weeks, Joan How, Anna E Marneth, Jason Gotlib, Vikas Gupta, Ann Mullally
Förderung
- Deutsche Krebshilfe (German Cancer Aid)
- NCI NIH HHS
- NHLBI NIH HHS
- Starr Foundation
- U.S. Department of Defense (United States Department of Defense)
- U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- Honoraria from GSK and Novartis
Zitieren
APA
Rolles, B., Filho, C. M. O., Fergusson, N., Bewersdorf, J. P., Keating, J., Perkins, C., Schwede, M., England, J., Luskin, M. R., DeAngelo, D. J., Shimony, S., Faiz, M., Hillerbrand, A. C., Kim, C., Weeks, L. D., Waldman, L., Wazir, M., How, J., Marneth, A. E., …, & Mullally, A. (2026). Risk stratification of patients with TP53-mutated myeloproliferative neoplasms. Leukemia. https://doi.org/10.1038/s41375-026-02885-7
Vancouver
Rolles B, Filho CMO, Fergusson N, Bewersdorf JP, Keating J, Perkins C, et al. Risk stratification of patients with TP53-mutated myeloproliferative neoplasms. Leukemia. 2026. doi:10.1038/s41375-026-02885-7
BibTeX
@article{Rolles2026,
author = {Rolles, Benjamin and Filho, Cilomar Martins de Oliveira and Fergusson, Nathan and Bewersdorf, Jan Philipp and Keating, Julia and Perkins, Cecelia and Schwede, Matthew and England, James and Luskin, Marlise R and DeAngelo, Daniel J and Shimony, Shai and Faiz, Mifra and Hillerbrand, Addison C and Kim, Chulwoo and Weeks, Lachelle D and Waldman, Lauren and Wazir, Mohammed and How, Joan and Marneth, Anna E and Liu, Yiwen and Aryee, Martin J and Rampal, Raajit and Tsai, Harrison K and Gotlib, Jason and Gupta, Vikas and Stahl, Maximilian and Mullally, Ann},
title = {Risk stratification of patients with TP53-mutated myeloproliferative neoplasms},
journal = {Leukemia},
year = {2026},
doi = {10.1038/s41375-026-02885-7}
}
EUVIMED